Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma

Journal of Pediatric Surgery

Volumn 39, Issue 10, 2004, Pages 1512-1519

  Li, Peng ^a,b   Gao, Ya ^a   Ji, Zongzheng ^a   Zhang, Xiansheng ^a   Xu, Quan ^a   Li, Gongcai ^a   Guo, Zhengtuan ^a   Zheng, Baijun ^a   Guo, Xinkui ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

neuroblastoma; Urokinase plasminogen activator; urokinase plasminogen activator receptor

Indexed keywords

GENE PRODUCT; UROKINASE; UROKINASE RECEPTOR;

AGE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

CHILD; CHILD, PRESCHOOL; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 5344250941     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2004.06.011     Document Type: Article

References (46)

1. Fidler I.J., Gersten D.M., Hart I.R. The biology of cancer invasion and metastasis. Adv Cancer Res. 28:1978;149-150
2. Chikahisa L., Matsuo K., Yamada Y. Modulation of tumor cell motility by plasmin. Invasion Metastasis. 17:1997;323-333
3. Lyden P.D., Zivin J.A., Clark W.A., et al. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology. 39:1989;703-708
4. Gupta A.A., Leaker M., Andrew M., et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr. 139:2001;682-688
5. Rettenberger P., Wilhelm O., Oi H., et al. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. Biol Chem Hoppe Seyler. 376:1995;587-594
6. Schmitt M., Janicke F., Moniwa N., et al. Tumor-associated urokinase-type plasminogen activator Biological and clinical significance. Biol Chem Hoppe Seyler. 373:1992;611-622
7. Plesner T., Behrendt N., Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 15:1997;398-408
8. Vassalli J.-D., Sappino A.P., Belin D. The plasminogen activator' plasmin system. J Clin Invest. 88:1991;1067-1072
9. Xue W., Mizukami I., Todd R.F. 3rd, et al. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells Dependence on extracellular matrix components. Cancer Res. 57:1997;1682-1689
10. Festuccia C., Dolo V., Guerra F., et al. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis. 16:1998;513-528
11. Miyake H., Hara I., Yamanaka K., et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 39:1999;123-129
12. Volm M., Mattern J., Koomagi R. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol Rep. 6:1999;611-615
13. Tecimer C., Doering D.L., Goldsmith L.J., et al. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer. 10:2000;372-381
14. Borstnar S., Vrhovec I., Svetic B., et al. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin Breast Cancer. 3:2002;138-146
15. Okusa Y., Ichikura T., Mochizuki H., et al. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. Int J Oncol. 17:2000;1001-1005
16. Gao Ya, Li Gongcai, Zhang Xiansheng, et al. Detection of neuroblastoma cells in blood by reverse transcriptase ployerase chain reaction. Chin Med J. 110:1997;341-345
17. Brodeur G.M., Pritchard J., Berthold, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 11:1993;1466-1477
18. Shimada H., Ambros I.M., Dehner L.P., et al. The international Neuroblastoma Pathology Classification (the Shimada system). Cancer. 86:1999;364-372
19. Friess H., Yamanaka Y., Buchler M., et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 105:1993;1846-1856
20. Miturski R., Semczuk A., Tomaszewski J., et al. bcl-2 protein expression in endometrial carcinoma The lack of correlation with p53. Cancer Lett. 13:(133):1998;63-69
21. Ambros I.M., Zellner A., Roald B., et al. Role of ploidy, chromo-some 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med. 334:1996;1505-1511
22. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N-myc oncocene with rapid progression of neuroblastoma. N Engl J Med. 313:1985;1111-1116
23. Ambros P.F., Ambros I.M., Strehl S., et al. Regression and progression in neuroblastoma. Does genetics predict tumor behavior? Eur J Cancer. 31A:1995;510-515
24. Martinsson T., Sjoberg R.M., Hedborg F., et al. Deletion of chromosome 1 p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 55:1995;5681-5686
25. Falkmer U.G., Falkmer S. The value of cytometric DNA analysis as a prognostic tool in neuroendocrine neoplastic diseases. Pathol Res Pract. 191:1995;281-303
26. Takeda S., Nakao A. Genetic detection and clinical applications in patients with hepatocellular carcinoma. Nippon Geka Gakkai Zasshi. 103:2002;472-475
27. Shin J.H., Chung J., Kim H.O., et al. Detection of cancer cells in peripheral blood of stomach cancer patients using RT-PCR amplification of tumour-specific mRNAs. Aliment Pharmacol Ther. 16:(suppl 2):2002;137-144
28. Mattano J.A., Moss T.J., Emerson S.G., et al. Sensitive detection of circulating neuroblastoma cells by reverse transcriptase-polymerase chain reaction. Cancer Res. 52:1992;4701
29. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth invasion and metastasis. Cell Mol Life Sci. 57:2000;25-40
30. Wei Y., Yang X., Simon D.I., et al. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 144:1999;1285-1294
31. Chambers S.K., Ivins C.M., Carcangiu M.L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Caner. 79:1998;449-454
32. Danen E.H., Lafrenie R.M., Miyamoto S., et al. Integrin signaling Cytoskeletal complexes, MAP kinase activation and regulation of gene expression. Cell Adhes Commun. 6:1998;217-224
33. Berger D.H. Plasmin/Plasminogen system in colorectal cancer. World J Surg. 26:2002;767-771
34. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J Clin Oncol. 17:1999;2264-2279
35. Brodeur G.M., Seeger R.C., Sather H., et al. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science. 224:1984;1121-1124
36. Seeger R.C., Brodeur G.M., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med. 313:1985;1111-1116
37. Schweigerer L., Breit S., Wenzel A., et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells Evidence for induction of autocrine growth factor activity. Cancer Res. 50:1990;4411-4416
38. Gross N., Miescher G., Beck K., et al. Altered growth and phenotype in clonal mycN transfectans of the SK-N-SH neuroblastoma cell line. Int J Cancer. 59:1994;141-148
39. Schmidt M.L., Salwen H.R., Manohar C.F., et al. The biological effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ. 5:1994;171-178
40. Negroni A., Scarpa S., Romeo A., et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ. 2:1991;511-518
41. Look A.T., Hayes F.A., Nitschke R., et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 311:1984;231-235
42. Taylor S.R., Locker J. A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer. 65:1990;1360-1366
43. Bourhis J., Devathaire F., Wilson G.D., et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 51:1991;33-36
44. Gansler T., Chatten J., Varello M., et al. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer. 58:1986;2453-2458
45. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17p and adverse outcome in patients with neuroblastoma. N Engl J Med. 340:1999;1954-1961
46. Mori T., Abe T., Wakabayashi Y., et al. Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J Neurooncol. 46:2000;115-123